BrainTale, a Paris, France-based adapted care company, raised €1m in seed funding.
The round comprises a loan from Bpifrance and Angels Santé, the instruction persuaded Paris Business Angels, Femmes Business Angels and Arts&Metiers Business Angels, as well as veterans from the medtech, investment and pharmaceutical industries.
Created in July 2018, BrainTale is dedicated to enable adapted care for brain injured patients in clinical routine with its portfolio of quantification and prediction digital medical devices in neurology and intensive care.
The company’s first CE marked product is brainQuant, a SaaS solution providing brain lesion quantification from diffusion MRI (Magnetic Resonance Imaging). BrainScore-coma, a SaaS solution combining brainQuant and artificial intelligence algorithms for predicting coma emergence of patients in intensive care after severe brain injuries is expected to receive CE marking by mid-2021.
BrainTale also has formed a Strategic Committee with the nominations of:
- Eric Garnier, representative of Angels Santé,
- Julien Vandewalle, representative of Paris Business Angels,
- professor Louis Puybasset, head of the Anesthesiology department at Pitié-Salpêtrière hospital in Paris (AP-HP Greater Paris University Hospitals),
- Julie Rachline, CEO of LallianSe & BrainTale and
- Vincent Perlbarg, BrainTale president.
The latter three cofounded the company with professors Lionel Velly, Damien Galanaud and Didier Cassereau.